About GBSciences
GBSciences is a company based in Las Vegas (United States) founded in 1967. The company has 2 employees. GBSciences offers products and services including PhAROS Drug Discovery Platform, Parkinson’s Disease Therapies, and COVID-Related Therapies. GBSciences operates in a competitive market with competitors including Tenaya Therapeutics, Cellino, Arrakis Therapeutics, MyoKardia and Eiger BioPharmaceuticals, among others.
- Headquarter Las Vegas, United States
- Employees 2
- Stage Public
- SectorsHealthcare
- Email••••••••
- Phone•••• ••••
- Website gbsciences.com
- Social LinkedIn X Facebook YouTube
- Legal Name Gb Sciences, Inc.
- Net Profit-$1.36 M (USD)66.99as on Mar 31, 2024
- EBITDA-$1.42 M (USD)11.84as on Mar 31, 2024
- Latest Funding Round$75K (USD), Post-IPO
Aug 2023
- Employee Count2
Products & Services of GBSciences
GBSciences offers a comprehensive portfolio of products and services, including PhAROS Drug Discovery Platform, Parkinson’s Disease Therapies, and COVID-Related Therapies.
AI platform for identifying effective drug combinations from plants.
Formulations for treating Parkinson's with plant-based mixtures.
Treatments to suppress hyperinflammation from COVID infections.
Apps and channels of GBSciences
its YouTube channel GB Sciences Inc OTCQB:GBLX has 186 subscribers and 30 videos.
Videos from GBSciences
The most watched videos on GBSciences's YouTube channel, GB Sciences Inc OTCQB:GBLX (186 subscribers). Click a video to play it here.
More on GB Sciences Inc OTCQB:GBLX.
Funding Insights of GBSciences
- Total Rounds 11
- Last Round Post-IPO — $75,000
- First Round $1.5M
(Apr 2014)
Latest 10 of 11 funding rounds of GBSciences with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Aug 2023 | $75,000 | Post-IPO | – | – | – |
| Jun 2022 | $25,000 | Post-IPO | – | – | – |
| Oct 2019 | $240,000 | Post-IPO | – | – | – |
| Oct 2019 | $2.93M | Post-IPO | – | – | – |
| Aug 2018 | $5M | Post-IPO | – | – | – |
| Jan 2018 | $7.2M | Post-IPO | – | – | – |
| Nov 2017 | $3.9M | Post-IPO | – | – | – |
| Mar 2017 | $2M | Post-IPO | – | – | – |
| Jan 2016 | $20,000 | Post-IPO | – | – | – |
| Jun 2014 | $2M | Post-IPO | – | – | – |
People of GBSciences
12 people are tracked at GBSciences (5 in leadership, 6 in board & advisors, 1 in team); the tracked headcount is 2.
| Name | Role | Group |
|---|---|---|
John Claybron Poss | CEO | Leadership |
Andrea L. Small-Howard | President & Chief Science Officer | Leadership |
Zach Swarts | Chief Financial Officer | Leadership |
John Clayborn Poss | CEO & Chairman | Leadership |
Michael Farley | President & Board Member, GBS Global Biopharma, Inc | Leadership |
Ed DeFrank | Board Member | Board & advisors |
Alexander Stokes | Scientific Advisory Board Member | Board & advisors |
Helen Turner | Scientific Advisory Board Member | Board & advisors |
Carlos F. Rios-Bedoya | Scientific Advisory Board Member | Board & advisors |
Zoltan Mari | Scientific Advisory Board Member | Board & advisors |
Norbert E. Kaminski | Scientific Advisory Board Member | Board & advisors |
Sebastian Meggers | Cultivation Manager | Team |
Complete people profiles for GBSciences
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
IPO & Listings of GBSciences
GBSciences is a publicly listed company on the OTC with ticker symbol GBLX in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- IPO date30 Dec 2003
- Listed onOTCMKTS: GBLX
- Listed entityGB Sciences, Inc.
- Exchange sectorHealth technology
- ISINUS3615441090
- Share price$0.00 · 2026-10-09
- Market capitalisation$40,707.00
- Volume (last session)7,325
Financials of GBSciences
| Year | Revenue | Net income | EBITDA |
|---|---|---|---|
| 2023 | – | -$1.4M | -$1.4M |
| 2022 | – | -$4.1M | -$1.6M |
| 2021 | – | -$530,870 | -$1.8M |
| 2020 | – | -$3.7M | -$1.9M |
| 2019 | – | -$12.4M | -$5.6M |
Detailed financial statements for GBSciences
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Timeline of GBSciences
4 dated milestones of GBSciences across 56 years, from founding to its latest funding, stage changes and deals.
- Founded GBSciences is founded.
- IPO Lists on the stock exchange (IPO).
- Funding First funding round of $1.5M.
- Funding Latest funding round, Post-IPO, of $75K.
Competitors of GBSciences
GBSciences operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Tenaya Therapeutics, Cellino, Arrakis Therapeutics, MyoKardia and Eiger BioPharmaceuticals, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| tenayatherapeutics.com | 2016 | San Francisco, United States | $142M | 140 | Regenerative and gene therapeutics for heart failure are developed. | |
| cellinobio.com | 2017 | Cambridge, United States | $125M | 63 | Developer of autologous cell therapies | |
| arrakistx.com | 2015 | Waltham, United States | $113M | 91 | Provider of tools for the analysis of RNA structures | |
| myokardia.com | 2012 | San Francisco, United States | $98M | 224 | Specialized drugs are developed for genetic heart diseases. | |
| eigerbio.com | 2000 | San Carlos, United States | $8.9M | 56 | Developer of antiviral agents against targets in the treatment of hepatitis | |
| cardurion.com | 2017 | Boston, United States | $270M | – | Therapeutics for heart and cardiovascular diseases are developed. | |
| esperion.com | 1998 | Ann Arbor, United States | $129.7M | 240 | Therapies for lowering low-density lipoprotein cholesterol levels are developed. | |
| portola.com | 2003 | San Francisco, United States | $296.09M | 369 | Therapeutics for cardiovascular and autoimmune diseases are developed. | |
| incardatherapeutics.com | 2009 | Palo Alto, United States | $79.7M | – | Inhaled therapies for acute cardiovascular symptoms are developed and delivered. |
Detailed competitors of GBSciences
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Gbsciences
Complete news archive for GBSciences
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Similar companies to GBSciences
10 companies that operate in the same segment as GBSciences (Cannabis Health Tech Ecosystem), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Cannabis products are provided to support consumer wellness and health. | 2013 | Smiths Falls, Ontario, Canada | – | USD 204.24 M | 960 | |
Online marketplace platform for cannabis traders | 2015 | New York, New York, United States | USD 195.4 M | – | – | |
Loyalty and marketing solutions for cannabis dispensaries are provided. | 2012 | West Palm Beach, Florida, United States | USD 25.79 M | USD 22.83 M | – | |
An online marketplace for cannabis products is operated. | 2017 | Bend, Oregon, United States | USD 603 M | – | 137 | |
Online platform for cannabis strains, reviews, and ratings | 2010 | Seattle, Washington, United States | USD 40.7 M | – | – | |
Provider of cannabis products, brands, and international business development investments | 2013 | Moncton, New Brunswick, Canada | – | USD 186.16 M | 898 | |
ERP software is offered via cloud platform for cannabis operations. | 2018 | Boston, Massachusetts, United States | – | USD 110.08 M | 313 | |
Online marketplace connecting licensed cannabis vendors and dispensaries | 2015 | Chicago, Illinois, United States | USD 22.57 M | – | – | |
Enterprise software is provided for cannabis dispensary management. | 2016 | Oakland, California, United States | USD 75.5 M | USD 148.97 K | 97 | |
Proprietary medical cannabis strains are developed and offered. | 2014 | Maryland Heights, Missouri, United States | USD 156 M | – | 557 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about GBSciences
GBSciences was founded in 1967 and raised its 1st funding round 47 years after it was founded.
GBSciences is headquartered in Las Vegas, United States. It is registered at Las Vegas, Nevada, United States.
John Claybron Poss is the current CEO of GBSciences.
GBSciences has 2 employees.
Founded in 1967 and headquartered in Las Vegas, United States, cannabinoid therapeutics are developed by the company for cardiovascular conditions, neurodegenerative diseases, inflammatory disorders, heart issues, and chronic pain. Proprietary formulations are included in the pipeline to address these areas within the biotechnology sector. Operations focus on research and development of targeted treatments.
GBSciences's top competitors include Esperion Therapeutics, Tenaya Therapeutics and Cellino.
GBSciences offers PhAROS Drug Discovery Platform, Parkinson’s Disease Therapies, and COVID-Related Therapies.
Yes, GBSciences is publicly traded on OTC under the ticker symbol GBLX.
GBSciences operates through Growblox Sciences, Inc..